Lyell Immunopharma Inc (LYEL)
1.43
+0.05
(+3.62%)
USD |
NASDAQ |
Jun 28, 16:00
1.45
+0.02
(+1.40%)
After-Hours: 20:00
Lyell Immunopharma Cash from Operations (Quarterly): -42.02M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -42.02M |
| December 31, 2023 | -40.64M |
| September 30, 2023 | -37.69M |
| June 30, 2023 | -39.16M |
| March 31, 2023 | -46.21M |
| December 31, 2022 | -40.27M |
| September 30, 2022 | -37.10M |
| June 30, 2022 | -44.33M |
| March 31, 2022 | -47.85M |
| Date | Value |
|---|---|
| December 31, 2021 | -33.21M |
| September 30, 2021 | -25.49M |
| June 30, 2021 | -33.95M |
| March 31, 2021 | -33.60M |
| December 31, 2020 | -26.73M |
| September 30, 2020 | -21.63M |
| June 30, 2020 | -88.92M |
| March 31, 2020 | -23.59M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-88.92M
Minimum
Jun 2020
-21.63M
Maximum
Sep 2020
-38.96M
Average
-37.69M
Median
Sep 2023
Cash from Operations (Quarterly) Benchmarks
| GlycoMimetics Inc | -10.51M |
| Candel Therapeutics Inc | -8.438M |
| Eliem Therapeutics Inc | -1.819M |
| Entrada Therapeutics Inc | -25.52M |
| NovaBay Pharmaceuticals Inc | -1.572M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 21.99M |
| Cash from Financing (Quarterly) | 0.027M |
| Free Cash Flow | -160.68M |
| Free Cash Flow Per Share (Quarterly) | -0.1654 |
| Free Cash Flow to Equity (Quarterly) | -42.05M |
| Free Cash Flow Yield | -44.56% |